Collegium Pharmaceutical (NasdaqGS:COLL) FY Conference December 02, 2025 02:30 PM ET Company ParticipantsColleen Tupper - CFOVikram Karnani - CEOConference Call ParticipantsDavid Amsellem - Managing Director and Senior Research AnalystDavid AmsellemOkay, let's get started. Good afternoon everyone. This is David Amsellem from the Piper Sandler Biopharma team. Our next company fireside chat is Collegium. We have CEO Vikram Karnani with us. We also have CFO Colleen Tupper. Thanks so much for joining us. Let's ...

Group 1 - Recent significant temperature drops in northern regions have led to increased reports of joint and head pain, potentially linked to cold stimuli, migraines, and hypertension [1] - Over 50% of patients seek medical attention due to pain, with chronic pain often signaling underlying health issues such as leukemia or heart disease [1] - Chronic pain lasting over three months can lead to depression and sleep disorders, affecting overall health and quality of life [1] Group 2 - There are many effective treatments for pain, and conditions like shingles and migraines should not be endured without timely intervention [3] - The prevalence of migraines is around 10%, particularly among individuals aged 20 to 40, and early medication is advised during migraine attacks [4] - For mild migraines, non-steroidal anti-inflammatory drugs (NSAIDs) can be used, while moderate to severe cases may require more targeted medications under professional guidance [4] Group 3 - Concerns about dependency on pain medications are addressed, with a distinction made between opioid and non-opioid analgesics [6] - Non-opioid analgesics like acetaminophen and ibuprofen are considered safe when used as directed and do not lead to addiction [8] - Cases of addiction to opioids are rare when these medications are used at standard doses and in a regulated manner [10]

持续聚焦于疼痛领域有潜力的离子通道靶标。 本文为IPO早知道原创 作者｜Stone Jin 微信公众号｜ipozaozhidao 据IPO早知道消息，阳光安津（南京）生物医药科技有限公司（以下简称"阳光安津"）日前完成超亿 元Pre-A轮融资。本轮融资由启明创投领投，博行资本和清控银杏跟投。所募资金将用于全球领先的 疼痛治疗研发管线临床前和早期临床阶段的开发，加速靶向钠离子通道Nav1.8小分子药物的研发进 度，增强其在全球生物医药领域的竞争力。 阳光安津由北京大学雷晓光教授与中国医学科学院皮肤病医院临床医生杨勇教授共同创立， 现 已经 组建了在创新药物开发领域具有丰富研发经验和国际竞争力的研发团队，以新型镇痛药的研发为目 标，专注于Nav1.8和Nav1.7这两个与机体疼痛感受高度相关的钠离子通道。 当前，全球慢性疼痛发病率一直居高不下，根据国际疼痛协会数据，全世界1/5的人经历过慢性疼 痛。在中国，根据《中国疼痛防控与健康促进战略蓝皮书：中国疼痛医学发展报告》，有超过3亿人 正在遭受慢性疼痛的折磨，且正以每年1000万-2000万的速度快速增长，疼痛已成为继心脑血管疾 病、肿瘤之后的第三大健康问题。根据M ...